
Lambert-Eaton Myasthenic Syndrome is Underrecognized in Small Cell Lung Cancer: **An Analysis of Real-World Data**

¹Catalyst Pharmaceuticals, Coral Gables, FL, USA; ²University of Texas Southwestern Medical Center, Dallas, TX, USA; ³MedTech Analytics, LLC, Lexington, MA, USA; ⁴Northeast Epi, LLC, Bradford, NH, USA



- (3) The proportion of patients with LEMS and treated SCLC among those with treated SCLC and continuous healthcare utilization (\geq 12 months pre- and post-index SCLC claim)
- Patient demographic characteristics were assessed on index date; data were descriptive, and no statistical comparisons were performed
- The time between the earliest SCLC and LEMS diagnoses was assessed using the longitudinal LEMS dataset, which provided an additional 3 years of claims history (2014-2022)

Estimated patients with SCLC-LEMS in the US

David Morrell,¹ Benjamin Drapkin,² Guy Shechter,³ Regina Grebla⁴

- 867,170 US patients with lung cancer claims between 2017 and 2022 were identified
- 258 patients with lung cancer and LEMS claims were identified between October
- The prevalence of LEMS among patients with SCLC in the database during this period ranged from 0.16% (treated SCLC) to 0.24% (presumed SCLC) (Figure 2)
- Among the subset of 8,513 patients with treated SCLC and continuous healthcare

- Data on the timing of diagnoses (dx) were available for 83% (n=215/258) of SCLC-

- In 27%, the initial LEMS claim was >90 days after the index SCLC claim and the
- Among patients with treated SCLC-LEMS (n=76) with \geq 12 months claims history, the diagnosis of LEMS preceded SCLC by >90 days, or occurred within 90 days, in 76%
- LEMS lagged SCLC by ≥12 months in 12% (n=9/76) of treated SCLC-LEMS
- Initial claims that preceded SCLC by > 2 weeks were nearly always (75%; n=9/12)
- The diagnosed prevalence of SCLC and LEMS in this analysis was <1/10 of earlier published estimates of LEMS among patients with SCLC (Figure 4). This suggests
- Lung cancer cases in patients with LEMS were presumed to be SCLC in the absence of a specific ICD code for SCLC

*Among n=76/77 treated SCLC-LEMS patients with 12+ months claims history before lung cancer diagnosis; 13% based on published literature; 2Concurrent LEMS claims occurred ± 14 days of initial SCLC claim

There were 603,989 prevalent US lung cancer cases in 2020⁴

• The estimated number of patients with SCLC-LEMS in the US therefore ranges from 1,800 to 2,700*, among whom >90% were undiagnosed

• Assuming SCLC-LEMS accounts for approximately 50% of LEMS overall², we estimate the total number of US patients with LEMS to be in the range of 3,600 to 5,400 *Assumes SCLC accounts for 10-15% of lung cancer in the US and a 3% prevalence of SCLC-LEMS

Patient Characteristics


Most patients in this study with SCLC and LEMS were female, contrary to earlier published studies reporting most SCLC-LEMS cases were among males¹³

Table 1. Patient baseline characteristics assessed on the index date

	SCLC-LEMS ¹ N=258	Treated SCLC-LEMS ² N=77
Age, years, mean ± SD	66.1 ± 7.6	64.5 ± 7.0
Female, n (%)	144 (56)	42 (55)
Insurance coverage, n (%) ³		
Commercial	135 (52)	48 (62)
Medicare	70 (27)	16 (21)
Medicaid	17 (7)	4 (5)
Other ⁴	6 (2)	0 (0)
Unknown	30 (12)	9 (12)
Census Region, n (%)		
Northeast	53 (21)	16 (21)
Midwest	69 (27)	20 (26)
South	102 (40)	33 (43)
West	33 (13)	8 (10)
Unknown	1 (0.4)	0 (0)
Receipt of etoposide + platinum therapy, n (%)	77 (30)	77 (100)

¹Lung cancer cases are presumed to be SCLC in the absence of a specific ICD code for SCLC; ²For treated SCLC, which included receipt of etoposide and platinum therapy; ³Includes patients with government-sponsored insurance (n=1) and with a combination of insurance types.





in Southern US 52% insurance

received SCLC standard-ofwith commercial care therapies

LIMITATIONS

- Analyses were based on observational data and unmeasured confounding is possible
- As SCLC is not associated with a unique ICD code, there is potential for misclassification of patients with NSCLC and potential overestimation of the prevalence of LEMS among patients with SCLC Such misclassification in this analysis is unlikely because (1) LEMS is known to be associated with SCLC¹; and (2) analyses restricted to patients who received SCLC therapy yielded similar results.
- Patients with SCLC may not survive long enough to be diagnosed with LEMS
- The requirement of claims post-SCLC diagnosis in the sensitivity analysis risks introducing survival bias; however, this enables the estimation of SCLC-LEMS in the setting of LEMS diagnostic delay

CONCLUSIONS

- LEMS is the most common neurologic paraneoplastic disorder associated with SCLC, but among US patients LEMS may be underdiagnosed, as claims are less than 1/10 the estimated prevalence
- Because some non-specific LEMS symptoms may be attributed to SCLC or its treatment, comorbid LEMS may go unrecognized
- Underdiagnosis of LEMS and other PNS could lead to undertreatment, and standardized screening and paraneoplastic antibody testing may be warranted

REFERENCES

. O'Neill et al. Brain 1988;111(Pt 3):577-96 2. Titulaer et al. Lancet Neurol 2011;10(12):1098-107 3. Schoser et al. J Neurol 2017;264(9):1854-63 4. American Cancer Society. Key Statistics for Lung Cancer. 2023. 11. de la Monte et al. Am J Med 1984;77(5):851-7 5. Rudin et al. Nat Rev Dis Primers 2021;7(1):3 6. Maddison et al. Lancet 1999;353(9147):117-8 7. Wirtz et al. J Neuroimmunol 2005;164(1-2):161-5

8. Gozzard et al. Neurology 2015;85(3):235-9 9. Payne et al. J Thorac Oncol 2010;5(1):34-8 10. Ernani et al. Thorac Cancer 2022;13(7):925-33 12. Khan et al. JAMA Oncol 2016;2(11):1507-8

13. Wirtz et al. Clin Neurol Neurosurg 2002;104(4):359-63



DISCLOSURES

DM - employee, shareholder of Catalyst Pharmaceuticals; BD - consulting Sonata Therapeutics; GS, RG - consultants to Catalyst Pharmaceuticals

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without written permission of the authors